InMode to Report Third Quarter 2026 Financial Results on November 11, 2026, Expects Third Quarter Revenue of $91.8 Million to $92.0 Million, Reiterates FY 2026 Revenue Guidance Between $365M-$375M

InMode preliminarily expects Q3 2026 revenue of $91.8 million to $92.0 million; full-year 2026 revenue guidance remains $365 million to $375 million, consistent with prior guidance. Results are unaudited and subject to final closing adjustments, with final results due before the Nasdaq open on November 11. While its Special Committee evaluates a strategic proposal, the company will not hold an earnings call or webcast or conduct investor meetings at this time.

Analysis

The key market signal is not the narrow preliminary revenue range; it is the combination of unchanged annual guidance and an unresolved strategic proposal. With no call or investor meetings, investors have less opportunity to test assumptions about demand, margins, or the proposal’s process, increasing the chance that INMD trades on rumor and headline gaps rather than improving fundamentals. That information vacuum can widen the governance/uncertainty discount even if the quarter closes near the preliminary figure.

Near term, the November 11 release is a verification point, not necessarily a catalyst for a rerating: revenue alone will not establish earnings quality, cash conversion, or whether the strategic review is advancing. Over the next 1–3 months, the committee’s next communication and any disclosed proposal terms are the dominant catalysts. A credible transaction could support the equity, while delay, withdrawal, or unfavorable terms could unwind any deal premium. Over 6–18 months, absent a transaction, the stock must again be valued on standalone demand and execution; sustained softness in elective aesthetic spending or competitive substitution would matter more than this preliminary update.

Contrarian read: unchanged guidance may look reassuring, but without operating detail it does not resolve the underlying uncertainty. Conversely, treating the absence of a call as proof of deterioration is also unwarranted; it is explicitly tied to the committee’s evaluation. No evidence here supports a precise probability of a deal or a fundamental re-rating. Verify final results, cash-flow/earnings metrics, and the proposal’s status before taking material directional risk.

Key Decisions for Investors

• Keep INMD exposure sized for event risk; do not add solely on the preliminary revenue disclosure. The final November 11 release should be checked for any change to full-year guidance and for earnings and cash-flow details that the update does not provide.
• Treat the strategic review as a binary, unpriced catalyst: monitor for committee updates and disclosed proposal terms over the coming weeks. A delay, withdrawal, or terms that fail to establish credible value would falsify a deal-support thesis.
• Avoid an unhedged short ahead of a possible proposal update, since a favorable transaction headline could gap the shares higher. If existing exposure is material, consider defined-risk downside protection only after checking option pricing and liquidity; neither is supplied here.
• Reassess the standalone case if final results or later guidance weaken, or if subsequent disclosures indicate the strategic process has stalled. A stable revenue print by itself is insufficient confirmation of demand, margins, or valuation.